PainReform Announces PRF-110 Promoted Normal Wound Healing And Prevented Scar Formation Following Surgical Procedures; On Track To Report Top-Line Results From The Phase 3 Trial In The Second Half Of 2024
Portfolio Pulse from Benzinga Newsdesk
PainReform Ltd. (NASDAQ:PRFX) announced that its lead asset, PRF-110, promoted normal wound healing and prevented scar formation following surgical procedures. The company is on track to report top-line results from its Phase 3 trial in the second half of 2024.
August 05, 2024 | 1:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
PainReform Ltd. announced positive data for PRF-110, showing it promotes normal wound healing and prevents scar formation. The company is on track to report top-line results from its Phase 3 trial in the second half of 2024.
The positive data from the clinical trials and the reaffirmation of the timeline for Phase 3 results are likely to boost investor confidence in PainReform Ltd. This could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100